Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine

Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We developed a novel vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we used this novel vaccine platform to rapidly produce fully synthetic MVA (sMVA) vectors co-expressing SARS-CoV-2 spike and nucleocapsid antigens, two immunodominant antigens implicated in protective immunity. Mice immunized with these sMVA vectors developed robust SARS-CoV-2 antigen-specific humoral and cellular immune responses, including potent neutralizing antibodies. These results demonstrate the potential of a novel vaccine platform based on synthetic DNA to efficiently generate recombinant MVA vectors and to rapidly develop a multi-antigenic poxvirus-based SARS-CoV-2 vaccine candidate.

[1]  D. Burton,et al.  Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.

[2]  A. Sette,et al.  The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients , 2020, Science Immunology.

[3]  Y. Hu,et al.  Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial , 2020, The Lancet.

[4]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[5]  R. Baric,et al.  DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.

[6]  Daniel W. Kulp,et al.  Immunogenicity of a DNA vaccine candidate for COVID-19 , 2020, Nature Communications.

[7]  Barney S. Graham,et al.  Rapid COVID-19 vaccine development , 2020, Science.

[8]  Xinquan Wang,et al.  Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals , 2020, Immunity.

[9]  X. Tang,et al.  Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.

[10]  A. Iwasaki,et al.  The potential danger of suboptimal antibody responses in COVID-19 , 2020, Nature Reviews Immunology.

[11]  J. Bloom,et al.  Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays , 2020, bioRxiv.

[12]  N. Lurie,et al.  Developing Covid-19 Vaccines at Pandemic Speed. , 2020, The New England journal of medicine.

[13]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[14]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[15]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[16]  A. Nademanee,et al.  Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients , 2020, Annals of Internal Medicine.

[17]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[18]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[19]  G. Whittaker,et al.  Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting. , 2019, Journal of visualized experiments : JoVE.

[20]  D. Diamond,et al.  Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice , 2018, Journal of Virology.

[21]  S. Lederman,et al.  Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments , 2018, PloS one.

[22]  H. Yin,et al.  Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab , 2017, Oncoimmunology.

[23]  P. Earl,et al.  Generation of Recombinant Vaccinia Viruses , 2017, Current protocols in protein science.

[24]  I. Aldoss,et al.  MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults. , 2017, Blood.

[25]  G. Sutter,et al.  Modified Vaccinia Virus Ankara , 2016, Advances in Virus Research.

[26]  A. Herrmann,et al.  Human Cytomegalovirus Vaccine Based on the Envelope gH/gL Pentamer Complex , 2014, PLoS pathogens.

[27]  M. Carroll,et al.  Recombinant MVA vaccines: dispelling the myths. , 2013, Vaccine.

[28]  S. Gilbert.  Clinical development of Modified Vaccinia virus Ankara vaccines. , 2013, Vaccine.

[29]  A. Herrmann,et al.  A Vaccine Based on the Rhesus Cytomegalovirus UL128 Complex Induces Broadly Neutralizing Antibodies in Rhesus Macaques , 2012, Journal of Virology.

[30]  J. Peiris,et al.  Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcγR Pathway , 2011, Journal of Virology.

[31]  A. Mayr,et al.  Attenuierung von virulentem Hühnerpockenvirus in Zellkulturen und Eigenschaften des attenuierten Virus , 2010 .

[32]  Zhongde Wang,et al.  Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines , 2009, Vaccine.

[33]  P. Earl,et al.  Elucidating and Minimizing the Loss by Recombinant Vaccinia Virus of Human Immunodeficiency Virus Gene Expression Resulting from Spontaneous Mutations and Positive Selection , 2009, Journal of Virology.

[34]  A. Goesmann,et al.  Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. , 2007, The Journal of general virology.

[35]  J. von Einem,et al.  Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. , 2006, BioTechniques.

[36]  D. Tscharke,et al.  Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines , 2005, The Journal of experimental medicine.

[37]  W. Britt,et al.  Recombinant Modified Vaccinia Virus Ankara Expressing a Soluble Form of Glycoprotein B Causes Durable Immunity and Neutralizing Antibodies against Multiple Strains of Human Cytomegalovirus , 2004, Journal of Virology.

[38]  L. Casper,et al.  Dispelling the Myths , 2002 .

[39]  F. Falkner,et al.  The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. , 1998, Virology.

[40]  B. Moss,et al.  Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. , 1997, Virology.

[41]  B. Moss,et al.  Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. , 1996, Vaccine.

[42]  B. Moss,et al.  Nonreplicating vaccinia vector efficiently expresses recombinant genes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[43]  F. Falkner,et al.  Construction of chimeric vaccinia viruses by molecular cloning and packaging. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Merchlinsky.  Mutational analysis of the resolution sequence of vaccinia virus DNA: essential sequence consists of two separate AT-rich regions highly conserved among poxviruses , 1990, Journal of virology.

[45]  E. Paoletti,et al.  Protective immunity against avian influenza induced by a fowlpox virus recombinant. , 1988, Vaccine.

[46]  B. Moss,et al.  Molecular cloning and sequence of the concatemer junction from vaccinia virus replicative DNA. Viral nuclease cleavage sites in cruciform structures. , 1988, Journal of molecular biology.

[47]  G. McFadden,et al.  Efficient resolution of replicated poxvirus telomeres to native hairpin structures requires two inverted symmetrical copies of a core target DNA sequence , 1987, Journal of virology.

[48]  G. McFadden,et al.  Replication and resolution of cloned poxvirus telomeres in vivo generates linear minichromosomes with intact viral hairpin termini , 1986, Journal of virology.

[49]  B. Moss,et al.  Resolution of linear minichromosomes with hairpin ends from circular plasmids containing vaccinia virus concatemer junctions , 1986, Cell.

[50]  H. Birnboim,et al.  A rapid alkaline extraction procedure for screening recombinant plasmid DNA. , 1979, Nucleic acids research.

[51]  P. Barry,et al.  Exploiting 2A peptides to elicit potent neutralizing antibodies by a multi-subunit herpesvirus glycoprotein complex. , 2018, Journal of virological methods.

[52]  Gregory A. Smith,et al.  En passant mutagenesis: a two step markerless red recombination system. , 2010, Methods in molecular biology.

[53]  B. Moss,et al.  Structure and replication of vaccinia virus telomeres. , 1983, Cold Spring Harbor symposia on quantitative biology.

[54]  K. Malicki,et al.  [Attenuation of virulent fowl pox virus in tissue culture and characteristics of the attenuated virus]. , 1966, Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B.